Consultant Physician | University of Port Harcourt Teaching Hospital | Nigeria
Dr. Chizaram A. Onyeaghala is a Consultant Physician and Infectious Diseases Specialist at the University of Port Harcourt Teaching Hospital, Nigeria. His expertise lies in infectious diseases, HIV medicine, emerging and re-emerging infections, and global health. With a strong academic foundation, he holds qualifications from prestigious institutions, including the West African College of Physicians, the National Postgraduate Medical College of Nigeria, and advanced certifications in Vaccinology, Genomics, and Global Health from Stellenbosch University, Liverpool John Moores University, and the Royal College of Physicians, London. Dr. Onyeaghala’s research portfolio reflects a robust engagement with global health challenges. His works, cited over 837 times with an h-index of 11 and i10-index of 12, have been published in top-tier journals such as The Lancet Infectious Diseases, European Respiratory Journal, and Clinical Infectious Diseases. His collaborations with renowned institutions, including the University of Alabama at Birmingham, Queen Mary University of London, and Washington University in St. Louis, underscore his commitment to international scientific partnership and multidisciplinary inquiry. He has contributed to several landmark studies on Mpox, COVID-19, tuberculosis, antimicrobial resistance, and Lassa fever, which have informed clinical practice and public health response strategies in Nigeria and beyond. As a lead clinician in WHO- and LSTM-funded studies, and a member of national technical working groups, his research and leadership have had tangible societal impact—enhancing epidemic preparedness, infection prevention, and community health resilience. Dr. Onyeaghala’s professional engagements extend to editorial and review roles for international journals and active membership in organizations such as IDSA, IAS, ESCMID, and NIDS. His growing scholarly influence, mentorship activities, and policy-driven research continue to strengthen global infectious disease control and scientific innovation.
Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn
Featured Publications
-
Mitjà, O., Alemany, A., Marks, M., Mora, J. I. L., Rodríguez-Aldama, J. C., Silva, M. S. T., Onyeaghala, C. A., et al. (2023). Mpox in people with advanced HIV infection: A global case series. The Lancet, 401(10380), 939–949. https://doi.org/10.1016/S0140-6736(23)00273-3 — Citations: 480
-
Ogoina, D., Dalhat, M. M., Denue, B. A., Okowa, M., Chika-Igwenyi, N. M., Onyeaghala, C. A., et al. (2023). Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: A cohort study. The Lancet Infectious Diseases, 23(12), 1418–1428. https://doi.org/10.1016/S1473-3099(23)00409-7 — Citations: 49
-
Global Tuberculosis Network, Casco, N., Jorge, A. L., Palmero, D. J., Alffenaar, J. W., Fox, G. J., Onyeaghala, C. A., et al. (2023). Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort. European Respiratory Journal, 62(5). https://doi.org/10.1183/13993003.00925-2023 — Citations: 45
-
Migliori, G. B., Visca, D., van den Boom, M., Tiberi, S., Silva, D. R., Centis, R., Onyeaghala, C. A., et al. (2021). Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology, 27(3), 248–256. https://doi.org/10.1016/j.pulmoe.2020.12.016 — Citations: 41
-
Haeuser, E., Byrne, S., Nguyen, J., Raggi, C., McLaughlin, S. A., Bisignano, C., Onyeaghala, C. A., et al. (2025). Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: A systematic analysis for the Global Burden of Disease Study. The Lancet. — Citations: 26
